Advances in targeted medicine have benefited patients with certain kinds of lung cancer, but effective therapies for lung squamous cell carcinomas (LSCCs) remain in short supply. In a study recently published in Cell, Michael Gillette, a proteomics expert at the Broad Institute and Harvard University, and his colleagues scrutinized the molecular landscape of lung cancers to look for new treatment targets for LSCC.1
To get a clearer picture of the molecular landscape of LSCC, Gillette and colleagues probed nine data types, analyzing DNA, RNA, proteins, and post-translational modifications of more than 100 LSCC tumors. The “proteogenomic portrait” revealed unique therapeutic vulnerabilities for LSCC.
No cancer is good, but lung cancer is particularly deadly. Nearly twice as many people die from lung cancer worldwide as the second most fatal kind of cancer. Genomic discoveries have helped to identify targeted therapies for lung adenocarcinoma, the dominant subtype of lung cancer. But those ...
